Wellington Management Group LLP Sells 57,372 Shares of argenx SE (NASDAQ:ARGX)

Wellington Management Group LLP trimmed its position in shares of argenx SE (NASDAQ:ARGX) by 11.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 424,974 shares of the company’s stock after selling 57,372 shares during the period. Wellington Management Group LLP owned 0.70% of argenx worth $261,359,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the company. Steward Partners Investment Advisory LLC grew its stake in shares of argenx by 5.6% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company’s stock worth $234,000 after acquiring an additional 20 shares during the period. SG Americas Securities LLC lifted its holdings in argenx by 6.2% during the fourth quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock valued at $220,000 after purchasing an additional 21 shares during the last quarter. Farther Finance Advisors LLC boosted its position in argenx by 38.2% during the fourth quarter. Farther Finance Advisors LLC now owns 76 shares of the company’s stock worth $47,000 after purchasing an additional 21 shares during the period. Dynasty Wealth Management LLC increased its stake in shares of argenx by 3.4% in the fourth quarter. Dynasty Wealth Management LLC now owns 677 shares of the company’s stock worth $416,000 after purchasing an additional 22 shares in the last quarter. Finally, Choreo LLC raised its position in shares of argenx by 4.4% in the fourth quarter. Choreo LLC now owns 551 shares of the company’s stock valued at $342,000 after purchasing an additional 23 shares during the period. 60.32% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Guggenheim raised their price objective on shares of argenx from $775.00 to $1,100.00 and gave the stock a “buy” rating in a report on Monday, March 10th. JMP Securities lifted their price target on argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a research report on Tuesday, January 14th. William Blair reissued an “outperform” rating on shares of argenx in a report on Friday, February 28th. Sanford C. Bernstein raised argenx from a “market perform” rating to an “outperform” rating in a report on Monday, March 17th. Finally, Piper Sandler increased their price target on shares of argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a report on Tuesday, January 7th. Three analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, argenx has an average rating of “Moderate Buy” and a consensus target price of $687.00.

argenx Price Performance

Shares of NASDAQ ARGX opened at $567.09 on Wednesday. The stock has a market capitalization of $34.46 billion, a P/E ratio of -644.42 and a beta of 0.59. argenx SE has a one year low of $352.77 and a one year high of $678.21. The firm’s 50 day simple moving average is $625.68 and its two-hundred day simple moving average is $602.71.

argenx (NASDAQ:ARGX) last released its earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. As a group, equities analysts expect that argenx SE will post 3.13 earnings per share for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.